PCM
COYA icon

Potomac Capital Management’s Coya Therapeutics COYA Stock Holding History

Potomac Capital Management’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$156K Buy
+21,101
New +$117K 0.18% 51

Other funds holding COYA

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Potomac Capital Management's COYA Position: Q4 2023 in Review

Potomac Capital Management opened a new position in Coya Therapeutics (COYA) in Q4 2023: 21,101 shares worth $156K. The stake represents 0.18% of the portfolio and ranks #51 among its holdings.

21 funds tracked by Wall St. Rank hold COYA as of Q4 2023.

  • Potomac Capital Management held 21,101 shares of Coya Therapeutics worth $156K as of Q4 2023.
  • Coya Therapeutics was a new Potomac Capital Management position in Q4 2023.
  • Coya Therapeutics made up 0.18% of Potomac Capital Management's portfolio in Q4 2023, its #51 holding.
  • 21 funds tracked by Wall St. Rank held Coya Therapeutics as of Q4 2023.

Based on Potomac Capital Management's 13F filing for Q4 2023, filed 15 Feb 2024.